Antonio Cebriá
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Antonio Cebriá has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Joaquín Pastor
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain
9 shared publications - María Isabel Albarrán
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain
8 shared publications - Carmen Blanco-Aparicio
Experimental Therapeutics Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain
6 shared publications David Cebrián
Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain
6 shared publications- Julen Oyarzabal
Small Molecule Discovery Platform, Molecular Therapeutics Program, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
6 shared publications - Sonia Martínez
Experimental Therapeutics Programme Spanish National Cancer Research Centre (CNIO) Madrid Spain
5 shared publications
Latest Publications
- 1 November 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 224, 113703
Corrigendum to <’ Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors’ [Eur. J. Med. Chem. 211 (2021), 113109]
- 1 November 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 224, 113703
Corrigendum to <’ Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors’ [Eur. J. Med. Chem. 211 (2021), 113109]
- 1 April 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 168, 87-109
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors
- 1 April 2019
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 168, 87-109
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors
- 1 November 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (21) , 4794-4799
Identification of novel PI3K inhibitors through a scaffold hopping strategy
- 1 November 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (21) , 4794-4799
Identification of novel PI3K inhibitors through a scaffold hopping strategy
- 1 June 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (11) , 2536-2543
Generation of tricyclic imidazo[1,2- a ]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy
- 1 June 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (11) , 2536-2543
Generation of tricyclic imidazo[1,2- a ]pyrazines as novel PI3K inhibitors by application of a conformational restriction strategy
- Open Access
- 9 December 2014
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (6) , 482
A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes
Introduction: The activation of the phosphoinositide 3-kinase (PI3K)/AKT signalling pathway is one the most frequent genetic events in breast cancer, consequently the development of PI3K inhibitors has attracted much attention. Here we evaluate the effect of PI3K inhibition on global gene expression in breast cancer cells. Methods: We used a range of methodologies that include in silico compound analysis, in vitro kinase assays, cell invasion assays, proliferation assays, genome-wide transcription studies (Agilent Technologies full genome arrays), gene set enrichment analysis, quantitative real-time PCR, immunoblotting in addition to chromatin immunoprecipitation. Results: We defined the physico-chemical and the biological properties of ETP-45658, a novel potent PI3K inhibitor. We demonstrated that ETP-45658 potently inhibited cell proliferation within a broad range of human cancer cells, most potently suppressing the growth of breast cancer cells via inhibiting cell cycle. We show that this response is Forkhead box O (FOXO) protein dependent and p53 independent. Our genome-wide microarray analysis revealed that the cell cycle was the most affected biological process after exposure to ETP-45658 (or our control PI3K inhibitor PI-103), that despite the multiple transcription factors that are regulated by the PI3K/AKT signalling cascade, only the binding sites for FOXO transcription factors were significantly enriched and only a subset of all FOXO-dependent genes were induced. This disparity in gene transcription was not due to differential FOXO promoter recruitment. Conclusions: The constitutive activation of PI3Ks and thus the exclusion of FOXO transcription factors from the nucleus is a key feature of breast cancer. Our results presented here highlight that PI3K inhibition activates specific FOXO-dependent genes that mediate cell cycle arrest in breast cancer cells.
- 9 December 2014
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (6) , 482
Open AccessA novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes
Introduction: The activation of the phosphoinositide 3-kinase (PI3K)/AKT signalling pathway is one the most frequent genetic events in breast cancer, consequently the development of PI3K inhibitors has attracted much attention. Here we evaluate the effect of PI3K inhibition on global gene expression in breast cancer cells. Methods: We used a range of methodologies that include in silico compound analysis, in vitro kinase assays, cell invasion assays, proliferation assays, genome-wide transcription studies (Agilent Technologies full genome arrays), gene set enrichment analysis, quantitative real-time PCR, immunoblotting in addition to chromatin immunoprecipitation. Results: We defined the physico-chemical and the biological properties of ETP-45658, a novel potent PI3K inhibitor. We demonstrated that ETP-45658 potently inhibited cell proliferation within a broad range of human cancer cells, most potently suppressing the growth of breast cancer cells via inhibiting cell cycle. We show that this response is Forkhead box O (FOXO) protein dependent and p53 independent. Our genome-wide microarray analysis revealed that the cell cycle was the most affected biological process after exposure to ETP-45658 (or our control PI3K inhibitor PI-103), that despite the multiple transcription factors that are regulated by the PI3K/AKT signalling cascade, only the binding sites for FOXO transcription factors were significantly enriched and only a subset of all FOXO-dependent genes were induced. This disparity in gene transcription was not due to differential FOXO promoter recruitment. Conclusions: The constitutive activation of PI3Ks and thus the exclusion of FOXO transcription factors from the nucleus is a key feature of breast cancer. Our results presented here highlight that PI3K inhibition activates specific FOXO-dependent genes that mediate cell cycle arrest in breast cancer cells.
- 24 May 2012
- Published by Springer Nature in Investigational New Drugs
- Vol. 31 (1) , 66-76
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
Inhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling pathway is activated in a variety of solid and non-solid tumors. We have identified an imidazopyrazine derivative, ETP-46321, as a potent inhibitor of PI3Kα $ {\text{K}}_{\text{i}}^{\text{app}} = {2}.{\text{4 nM}} $ . The compound was 6 times less potent towards PI3Kδ and more than 200 and 60 times less potent at inhibiting PI3Kβ and PI3Kγ and did not significantly inhibit the related phosphoinositide-3-kinase-related protein kinase family kinases mTOR or DNA PK (IC50’s > 5 μM), or an additional 287 protein kinases that were screened. ETP-46321 inhibited PI3K signaling in treated tumor cell lines, induced cell cycle arrest and inhibited VEGF-dependent sprouting of HUVEC cells. The compound was anti-proliferative and synergized with both cytotoxic and targeted therapeutics. The compound induced a reduction in the phosphorylation of Akt in U87 MG xenografts after a single treatment. The growth of colon and lung cancinoma HT-29 and A549 xenografts was delayed by once a day treatment with ETP-46321. The compound synergized with Doxotaxel in a model of ovarian cancer.- 24 May 2012
- Published by Springer Nature in Investigational New Drugs
- Vol. 31 (1) , 66-76
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
Inhibitors of PI3K signaling are of great therapeutic interest in oncology. The phosphoinositide-3-kinase signaling pathway is activated in a variety of solid and non-solid tumors. We have identified an imidazopyrazine derivative, ETP-46321, as a potent inhibitor of PI3Kα $ {\text{K}}_{\text{i}}^{\text{app}} = {2}.{\text{4 nM}} $ . The compound was 6 times less potent towards PI3Kδ and more than 200 and 60 times less potent at inhibiting PI3Kβ and PI3Kγ and did not significantly inhibit the related phosphoinositide-3-kinase-related protein kinase family kinases mTOR or DNA PK (IC50’s > 5 μM), or an additional 287 protein kinases that were screened. ETP-46321 inhibited PI3K signaling in treated tumor cell lines, induced cell cycle arrest and inhibited VEGF-dependent sprouting of HUVEC cells. The compound was anti-proliferative and synergized with both cytotoxic and targeted therapeutics. The compound induced a reduction in the phosphorylation of Akt in U87 MG xenografts after a single treatment. The growth of colon and lung cancinoma HT-29 and A549 xenografts was delayed by once a day treatment with ETP-46321. The compound synergized with Doxotaxel in a model of ovarian cancer.- 1 March 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (5) , 1874-1878
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors
- 1 March 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (5) , 1874-1878
Imidazo[1,2-a]pyrazines as novel PI3K inhibitors
- 1 February 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (4) , 1591-1597
Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors
- 1 February 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (4) , 1591-1597
Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors
- 12 November 2011
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (11_Supplem) , B227
Abstract B227: Discovery of 3-aryl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-ylamine compounds as potent, selective and orally bioavailable inhibitors of PIM kinases.
The PIM family of serine/threonine kinases (PIM-1, 2 and 3) has been originally identified as proviral integration sites involved in lymphomagenesis induced by murine leukemia virus. In almost all of the MuLV-induced lymphomas in Eμ-Pim-1 transgenic mice either c-MYC or N-MYC is activated by proviral insertion. The oncogenic properties of Pim kinases were shown to encompass their capacity to counteract the increased sensitivity to apoptosis induction that is associated with MYC-driven tumorigenesis. Pim-1, 2 and 3 are highly conserved kinases that have unique structural properties, and are characterized by a constitutive serine/threonine activity that does not depend on post-translational modifications for activation. Pim kinases activity supports in vitro and in vivo tumor cell growth and survival through modification of an increasing number of common as well as isoform-specific substrates. Pim expression is driven by oncogenes as BCR-ABL, JAK2, FLT3 and KRas. Pim kinases are overexpressed in a range of haematopoietic malignancies and solid cancers, and its overexpression is associated with drug resistance. Inhibition of PIM kinase activity may be an attractive therapeutic strategy with possible favourable toxicity profiles due to minimal phenotype of mice mutant for all Pim family members. Based on the knowledge of complexes of ligands with PIM1 protein, previously reported, as well as known PIM1 inhibitors coming from and internal HTS campaign, we carried out a scaffold hopping strategy for hit generation. We identified triazolopyridine compounds with potent activity against PIM and FLT3 kinases. We have explored different substitution patterns to improve selectivity of PIM vs FLT3 activity. Here, we describe the exploration and biological characterization of this bicyclic series, reporting its SAR/SPR (ADME). We identified lead compounds with potency in the low nanomolar range vs. PIM1, 2 and 3 and high selectivity versus a panel of 24 protein kinases. The compounds display cellular activity by blocking PIM signaling, S112 P-Bad in H1299 Pim1 cells, in the low nanomolar range. The combination of the PI3K inhibitor GDC-0941 with Pim inhibitors was strongly synergistic in vitro in non solid and solid tumoral cell lines. Finally, we assessed the effect of Pim kinase inhibition on Pim signaling and tumor growth in vivo in a mouse intravenous tumor xenograft model employing tumoral cells coming from E myc mice and in an inducible transgenic KRasV12 mouse model. When delivered orally, ETP-995 inhibited phosphorylation of bad and 4EBP and reduced c-myc expression in vivo, and the compound significantly inhibited tumor growth. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B227.
- 12 November 2011
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 10 (11_Supplem) , B227
Abstract B227: Discovery of 3-aryl-3H-[1,2,3]triazolo[4,5-b]pyridin-5-ylamine compounds as potent, selective and orally bioavailable inhibitors of PIM kinases.
The PIM family of serine/threonine kinases (PIM-1, 2 and 3) has been originally identified as proviral integration sites involved in lymphomagenesis induced by murine leukemia virus. In almost all of the MuLV-induced lymphomas in Eμ-Pim-1 transgenic mice either c-MYC or N-MYC is activated by proviral insertion. The oncogenic properties of Pim kinases were shown to encompass their capacity to counteract the increased sensitivity to apoptosis induction that is associated with MYC-driven tumorigenesis. Pim-1, 2 and 3 are highly conserved kinases that have unique structural properties, and are characterized by a constitutive serine/threonine activity that does not depend on post-translational modifications for activation. Pim kinases activity supports in vitro and in vivo tumor cell growth and survival through modification of an increasing number of common as well as isoform-specific substrates. Pim expression is driven by oncogenes as BCR-ABL, JAK2, FLT3 and KRas. Pim kinases are overexpressed in a range of haematopoietic malignancies and solid cancers, and its overexpression is associated with drug resistance. Inhibition of PIM kinase activity may be an attractive therapeutic strategy with possible favourable toxicity profiles due to minimal phenotype of mice mutant for all Pim family members. Based on the knowledge of complexes of ligands with PIM1 protein, previously reported, as well as known PIM1 inhibitors coming from and internal HTS campaign, we carried out a scaffold hopping strategy for hit generation. We identified triazolopyridine compounds with potent activity against PIM and FLT3 kinases. We have explored different substitution patterns to improve selectivity of PIM vs FLT3 activity. Here, we describe the exploration and biological characterization of this bicyclic series, reporting its SAR/SPR (ADME). We identified lead compounds with potency in the low nanomolar range vs. PIM1, 2 and 3 and high selectivity versus a panel of 24 protein kinases. The compounds display cellular activity by blocking PIM signaling, S112 P-Bad in H1299 Pim1 cells, in the low nanomolar range. The combination of the PI3K inhibitor GDC-0941 with Pim inhibitors was strongly synergistic in vitro in non solid and solid tumoral cell lines. Finally, we assessed the effect of Pim kinase inhibition on Pim signaling and tumor growth in vivo in a mouse intravenous tumor xenograft model employing tumoral cells coming from E myc mice and in an inducible transgenic KRasV12 mouse model. When delivered orally, ETP-995 inhibited phosphorylation of bad and 4EBP and reduced c-myc expression in vivo, and the compound significantly inhibited tumor growth. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B227.
- Open Access
- 1 October 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (41) , 28392-28400
Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases
- 1 October 2009
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 284 (41) , 28392-28400
Open AccessChemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases